Nephrocare Health Services Q3 FY26: 31.7% Revenue Growth, 71% PAT Jump & 24.7% ROCE — Is India’s Dialysis King Just Getting Started?
1. At a Glance – The Dialysis Machine That Prints Cash (Three Times a Week)
Nephrocare Health Services Ltd is not your typical hospital stock. It’s a recurring revenue engine where patients show up three times a week — not because of loyalty points, but because survival demands it.
This company handles roughly 10% of India’s dialysis load, runs 519 clinics globally, and did 1.87 million treatments in just H1 FY26. Utilisation? 75%. Revenue per treatment? ₹2,531.
And here’s the kicker — international revenue is now 41% of operations in 9M FY26. Translation: They’re no longer just an India story.
But at 73x earnings, are we paying for a healthcare hero… or a growth fantasy?
Let’s plug into the machine.
2. Introduction – Dialysis, Discipline & Dollar Signs
India has many healthcare companies. Most of them depend on episodic illness. You fall sick. You go. You pay. You leave.
Dialysis? Different beast.
If you need it, you need it for life — usually three times a week. That’s 156 visits a year. That’s not customer retention. That’s medically enforced subscription.
Nephrocare built an asset-light dialysis empire by partnering with hospitals and governments instead of building giant super-speciality castles.
They operate through:
Captive hospital clinics (inside Max, Fortis, CARE, etc.)
PPP clinics inside government hospitals
Standalone centres in Tier II/III towns
Home dialysis, dialysis-on-wheels, on-call models
IPO came in December 2025. They raised ₹871 Cr. Fresh issue ₹353 Cr for expansion and debt repayment.
Now the real question:
Can dialysis scale like diagnostics? Can margins survive international expansion? And can a 73 P/E be justified?
Let’s break it down clinically.
3. Business Model – WTF Do They Even Do?
Imagine this.
A hospital has space. It doesn’t want dialysis headache.
Nephrocare walks in and says:
“You give space. We bring machines, staff, processes, procurement muscle. We split revenue.”
Boom. Captive clinic.
Or government says:
“Provide dialysis for public hospitals.”
Nephrocare sets up PPP model — fixed reimbursement, high volume, no rent.
Standalone centres? For Tier II/III towns where demand exists but hospitals don’t.
Revenue mix FY25:
India: 68%
International: 32%
Service mix:
Dialysis: 99%
Pharmacy/others: negligible
Revenue per treatment (9M FY26): ₹2,574 Q3 FY26 RPT: ₹2,642
Patients stick 95% of the time to the same centre. Switching is rare. Think of it like gym membership — except quitting isn’t an option.
Here’s the clever part:
International pricing is 3x–13x India.
Philippines, Uzbekistan, Saudi — they’re exporting Indian cost discipline to higher-paying geographies.
Would you prefer ₹22 per treatment or ₹300? Exactly.
4. Financials Overview – Show Me The Quarterly Money
